Skip to main content
. Author manuscript; available in PMC: 2014 May 1.
Published in final edited form as: Pharm Res. 2013 Feb 1;30(5):1447–1457. doi: 10.1007/s11095-013-0986-7

Figure 1. GW4064 treatment delays HFD-induced obesity in mice.

Figure 1

Fifteen-week-old C57BL/6 mice (male) were fed with HFD with or without inclusion of 0.2% cholesterol for 6 weeks. Mice were intraperitoneally injected by GW4064 (50 mg/kg, twice weekly) or carrier solution (DMSO) as the control. A, B, growth curve; C, D, fat and lean mass; E, F, food intake; G, H, H&E staining of white and brown adipose tissue. Each data point represents the average ± SD of 4 animals. *P<0.05 compared to DMSO-treated control animals. HFD-DMSO, HFD-GW4064: mice were fed with high-fat diet and treated with DMSO or GW4064; HFD-Chol-DMSO, HFD-Chol-GW4064: mice were fed with high-fat diet with 0.2% cholesterol and treated with DMSO or GW4064.